PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Muscle Malonyl Coa Biomarker Assay Development
- Conditions
- Healthy Volunteers
- Interventions
- Procedure: Muscle biopsy
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2010-11-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT01003444
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2010-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT01002963
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2010-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01002625
- Locations
- πΊπΈ
Pfizer Investigational Site, New York, New York, United States
Health Outcomes in Rheumatoid Arthritis in Greece
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: non interventional
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 210
- Registration Number
- NCT01001182
- Locations
- π¬π·
Pfizer Investigational Site, Thessaloniki, Greece
A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: reference [dextromethorphan]Drug: test [PF-00299804 + dextromethorphan]
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00999817
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
- Conditions
- Arthritis, PsoriaticPsoriasis
- Interventions
- Other: questionnaire
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2012-11-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 458
- Registration Number
- NCT00998829
- Locations
- π¦πΊ
Pfizer Investigational Site, Parkville, Victoria, Australia
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
- Conditions
- Cystitis, Interstitial
- Interventions
- Biological: TanezumabOther: Placebo
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 205
- Registration Number
- NCT00999518
- Locations
- πΊπΈ
Alabama Orthopaedic Clinic, Mobile, Alabama, United States
πΊπΈCoastal Clinical Research, Inc., Mobile, Alabama, United States
πΊπΈCanyon State Urology, Glendale, Arizona, United States
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 494
- Registration Number
- NCT00998764
- Locations
- πΊπΈ
University Of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUAB Center for Psychiatric Medicine, Birmingham, Alabama, United States
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 502
- Registration Number
- NCT00998309
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 198
- Registration Number
- NCT00996918
- Locations
- π¬π§
Pfizer Investigational Site, Swindon, United Kingdom